RaQualia Pharma, Inc. (4579) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Fuji Pharma Co., Ltd.

Koa Shoji Holdings Co., Ltd.

Taiko Pharmaceutical Co., Ltd.

Daito Pharmaceutical Co., Ltd.

Noile-Immune Biotech, Inc.

Seikagaku Corp.

Healios KK

Fuso Pharmaceutical Industries Ltd.

RaQualia Pharma, Inc.

SanBio Co., Ltd.

CanBas Co., Ltd.

Why is RaQualia Pharma, Inc. ?

Poor Management Efficiency with a low ROE of 4.41%

The company has been able to generate a Return on Equity (avg) of 4.41% signifying low profitability per unit of shareholders funds

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 4.41%

With a fall in Operating Profit of -1866.07%, the company declared Very Negative results in Jun 25

RAW MATERIAL COST(Y) Grown by 18.74% (YoY)
NET SALES(Q) Lowest at JPY 570.56 MM
INTEREST(Q) Highest at JPY 16.21 MM

Risky - Negative Operating Profits

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 205.63%, its profits have fallen by -114.4%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is RaQualia Pharma, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

RaQualia Pharma, Inc.

205.63%

1.45

78.40%

Japan Nikkei 225

28.54%

1.11

25.75%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

18.29%

EBIT Growth (5y)

2.10%

EBIT to Interest (avg)

62.14

Debt to EBITDA (avg)

22.67

Net Debt to Equity (avg)

0.06

Sales to Capital Employed (avg)

0.34

Tax Ratio

65.96%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

14.16%

ROE (avg)

4.41%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.00

EV to EBIT

-102.34

EV to EBITDA

69.76

EV to Capital Employed

2.88

EV to Sales

4.92

PEG Ratio

Dividend Yield

0.00%

ROCE (Latest)

-2.82%

ROE (Latest)

-8.11%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET SALES(9M)

At JPY 2,274.11 MM has Grown at 25.17%

NET PROFIT(HY)

Higher at JPY -361.82 MM

-18What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 18.74% (YoY

NET SALES(Q)

Lowest at JPY 570.56 MM

INTEREST(Q)

Highest at JPY 16.21 MM

OPERATING PROFIT(Q)

Lowest at JPY -163.91 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -28.73 %

PRE-TAX PROFIT(Q)

Lowest at JPY -331.32 MM

NET PROFIT(Q)

Lowest at JPY -360.22 MM

EPS(Q)

Lowest at JPY -15.25

Here's what is not working for RaQualia Pharma, Inc.

Net Sales

At JPY 570.56 MM has Fallen at -25.17%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit

At JPY -331.32 MM has Fallen at -90.17%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -360.22 MM has Fallen at -63.44%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Net Sales

Lowest at JPY 570.56 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Interest

Highest at JPY 16.21 MM

in the last five periods and Increased by 8.25% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Profit

Lowest at JPY -163.91 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Operating Profit Margin

Lowest at -28.73 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at JPY -331.32 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Net Profit

Lowest at JPY -360.22 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

EPS

Lowest at JPY -15.25

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (JPY)

Raw Material Cost

Grown by 18.74% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales